← Eichor
Condition: Refractory Al Amyloidosis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Refractory Al Amyloidosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With R
NA · 1 location(s) · Beijing Boren Hospital · NCT06983951A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidos
Phase 1/Phase 2 · 20 location(s) · Regeneron Pharmaceuticals · NCT06292780Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosi
Phase 1 · 9 location(s) · Gracell Biotechnologies (Shanghai) Co., Ltd. · NCT07250269Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
Phase 2 · 2 location(s) · Keymed Biosciences Co.Ltd · NCT07039578Registry of Older Patients With Cancer
Phase N/A · 7 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137825A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light
Phase 1 · 29 location(s) · Janssen Research & Development, LLC · NCT05652335Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
EARLY_Phase 1 · 1 location(s) · Beijing Boren Hospital · NCT076264763'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Phase 2 · 1 location(s) · Polina Stepensky · NCT06971380A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloido
Phase 1/Phase 2 · 18 location(s) · Alexion Pharmaceuticals, Inc. · NCT07081646Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01137643Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Phase 1/Phase 2 · 3 location(s) · University of Texas Southwestern Medical Center · NCT05145816Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Phase 1/Phase 2 · 1 location(s) · Brigham and Women's Hospital · NCT06569147
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.